Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/180373
Prognostic heterogeneity of adult B‐cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3‐PBX1 treated with measurable residual disease‐oriented protocols
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).
Matèries
Matèries (anglès)
Citació
Citació
RIBERA, Jordi, GRANADA, Isabel, MORGADES, Mireia, GONZÁLEZ, Teresa, CIUDAD, Juana, SUCH, Esperanza, CALASANZ, María josé, MERCADAL, Santiago, COLL, Rosa, GONZÁLEZ CAMPOS, José, TORMO, Mar, GARCÍA CADENAS, Irene, GIL, Cristina, CERVERA, Marta, BARBA, Pere, COSTA, Dolors, AYALA, Rosa, BERMÚDEZ, Arancha, ORFAO, Alberto, RIBERA, Josep maria, Programa Español de Tratamiento en Hematología (PETHEMA) Group Spanish Society Of Hematology (SEHH). Prognostic heterogeneity of adult B‐cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3‐PBX1 treated with measurable residual disease‐oriented protocols. _British Journal of Haematology_. 2021. Vol. 194. [consulta: 7 de febrer de 2026]. ISSN: 1365-2141. [Disponible a: https://hdl.handle.net/2445/180373]